

18th August 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I am conducting analysis on treatment with immunology medicines and kindly request your help.

I would be grateful if you could tell me how many patients were treated in the 3 months between April and June 2026 for the list of drugs named in the questions below.

Please fill in the template below with the number of patients or a format of your choice. Please include data for all hospitals in your organisation.

- How many patients were treated in total regardless of diagnosis with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data?**

Drug Name	Total number of patients treated regardless of diagnosis
Adalimumab	926
Etrasimod	0
Filgotinib	27
Golimumab	26
Guselkumab	26
Infliximab	270
Mirikizumab	10
Ozanimod	2
Risankizumab	51
Tofacitinib	20
Upadacitinib	96
Ustekinumab	324
Vedolizumab	137

2. How many patients were treated by the Gastroenterology Department or Clinic with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data?

Drug Name	Number of patients treated by the <u>Gastroenterology Department</u>
Adalimumab	289
Etrasimod	0
Filgotinib	11
Golimumab	1
Guselkumab	18
Infliximab	135
Mirikizumab	10
Ozanimod	2
Risankizumab	37
Tofacitinib	4
Upadacitinib	56
Ustekinumab	198
Vedolizumab	126

3. How many patients with Crohn's Disease, Ulcerative Colitis or Inflammatory Bowel Disease NOS in total regardless of department / clinic, were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data?

Drug Name	Number patients with <u>Crohn's Disease</u>	Number patients with <u>Ulcerative Colitis</u>	Number patients with <u>Inflammatory Bowel Disease NOS</u>
Adalimumab	189	96	0
Etrasimod	0	0	0
Filgotinib	0	11	0
Golimumab	0	1	0
Guselkumab	14	4	0
Infliximab	74	53	0
Mirikizumab	0	9	0
Ozanimod	0	2	0
Risankizumab	37	0	0
Tofacitinib	0	4	0
Upadacitinib	31	24	0
Ustekinumab	157	40	0
Vedolizumab	48	75	0

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm